Stay updated with breaking news from Frontier Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer. First PARP inhibitor to...
ICR welcomes OlympiA trial showing targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutationThe Institute of Cancer Research, London, strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have...
Press release content from Business Wire. The AP news staff was not involved in its creation.
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer ... | March 16, 2022
AstraZeneca and Merck have obtained the US Food and Drug Administration approval for Lynparza (olaparib) to treat early-stage breast cancer.